Abstract
Enrollment into clinical trials for kidney disease based on high albuminuria or low eGFR have not always yielded desired event rates. Recent data suggests that pre-trial eGFR slope may be a better tool to select trial participants. Few studies have attempted to estimate the improvement in prediction with biomarkers or a composite risk score beyond historical eGFR readings. KidneyIntelXTMis a composite risk score for DKD progression that incorporates static clinical variables and 3 plasma biomarkers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
